立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - linagliptinas - plėvele dengtos tabletės - 5 mg - linagliptin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - sitagliptinas - plėvele dengtos tabletės - 50 mg; 25 mg; 100 mg - sitagliptin

欧盟 - 立陶宛文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

欧盟 - 立陶宛文 - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metforminas hidrochloridas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - vokanamet yra nurodyta suaugusiems nuo 18 metų ir vyresni, su 2 tipo cukrinis diabetas, kaip papildoma priemonė kartu su dieta ir mankšta pagerinti glycaemic kontrolė:pacientams, nėra tinkamai kontroliuojamas jų maksimaliai toleruojamos dozės metforminas alonein pacientai, jų maksimaliai toleruojamos dozės metforminas kartu su kitais gliukozės mažinantys vaistai, įskaitant insuliną, jei šie nepateikia glycaemic kontrolės. pacientams, kurie jau gydomi derinys canagliflozin ir metforminas, kaip atskiras tabletsfor tyrimo rezultatus, susijusius su derinį terapija, poveikis glycaemic kontroliuoti širdies ir kraujagyslių įvykių, gyventojų, studijavo, žr. skirsnius 4. 4, 4. 5 ir 5.

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin

欧盟 - 立陶宛文 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.